AnalystBook Research · Company Intelligence

Quince Therapeutics, Inc.

QNCXNasdaq

Built from Quince Therapeutics, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Net income decreased 47.8% to ($84.0M), while Operating cash flow decreased 29.8% to ($41.4M).

The read at a glance✓ Audited against SEC data
  • ScaleFY2025 revenue N/AWatch
  • ProfitabilityNet income ($84.0M)Watch
  • Cash generationFree cash flow ($41.8M)Note
  • AccountingNo applicable forensic screenNote
  • Insiders0 buys; 1 sells in 365 daysNote
  • CapitalComparable payout data unavailableNote

Business

Quince Therapeutics, Inc.: We obtained the industry, market and similar data set forth in this report from our own internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies.

Leadership changes

From Quince Therapeutics, Inc.'s own filings, the day they're filed.

  • Brigette Roberts · Chief Executive Officer · appointmenteff. 2026-07-29
  • Keith Fandrick In · Chief Executive Officer · appointmenteff. 2026-07-29
  • Brigette Roberts · director · appointmenteff. 2026-05-18

Latest filings

  • 8-K · Company announcement2026-08-27
  • DEF 14A · Annual proxy (pay & governance)2026-08-25
  • 8-K · Company announcement2026-08-17
  • 10-Q · Quarterly report2026-08-14
  • 8-K · Company announcement2026-08-14
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Quince Therapeutics, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.